Understanding the Link Between Humira and Cancer
Humira (adalimumab) is a tumor necrosis factor-alpha (TNF-α) blocker used to treat certain autoimmune conditions like rheumatoid arthritis, Crohn's disease, and psoriasis. Research indicates Humira may increase the risk of certain cancers, especially when used long-term.
How Humira Works
Humira works by binding to TNF-α, a protein involved in inflammation. This reduces pain, swelling, and flare-ups in conditions like rheumatoid arthritis. However, TNF-α also helps regulate the immune system and destroy mutated cells that could become cancerous.
Humira and Cancer Risk
By inhibiting TNF-α, Humira may allow cancerous cells to grow unchecked. Studies show mixed findings on the exact cancer risk:
- A 2006 FDA review found no increased cancer risk with Humira use.
- A 2012 study found a 45% increased skin cancer risk with Humira after 36 months of use.
- A 2018 study reported a 57% increased melanoma risk specifically.
Research suggests the cancer risk may be higher with long-term use over 2-5 years. The potential also appears higher for certain cancers like skin cancers and lymphomas.
Specific Cancers Linked to Humira
Some cancers appear to have a stronger association with Humira use based on research to date. These include:
- Skin cancers - Increased risk of melanoma, squamous cell carcinoma, and basal cell carcinoma.
- Lymphoma - Both Hodgkin and non-Hodgkin lymphoma may occur more often.
- Lung cancer - Small increase seen in some studies.
- Bladder cancer - Possible slight increased risk.
Humira and Cancer Statistics
Statistical analysis can help shed light on the potential increased risk of cancer from Humira use. However, exact cancer rates are difficult to determine conclusively from available research data.
General Cancer Risk
Humira may raise overall cancer risk by about 30-50% compared to the general population when used long-term for 2+ years, according to some estimates. However, the baseline risk is still fairly low.
Melanoma Risk
One study found Humira was associated with about 4 additional melanoma cases per 1,000 patients after 36 months of use. Melanoma risk may be higher in those over 50 years old.
Lymphoma Risk
Data estimates Humira may increase lymphoma risk by 30-70%. This equates to about 6 extra cases per 10,000 patients with rheumatoid arthritis using the medication.
Lung Cancer Risk
Studies show those on Humira long-term have a lung cancer rate 1.5 times higher than TNF-inhibitor non-users. However, the baseline rate is still low at around 1 per 1,000.
Risk Factors for Humira-Associated Cancers
Certain factors appear to increase the risk of cancer from Humira use. These include:
- Older age (over 50 years old)
- Male gender
- Long-term use for 2-5+ years
- Combination with other immunosuppressants
- History of previous malignancy
- Genetic predisposition to cancer
- Smoking and other lifestyle-related cancer risk factors
Reducing Cancer Risk on Humira
If you take Humira
FAQs
What are the first signs of a flesh-eating bacteria infection?
Early signs include a localized red swollen area that is warm and painful. The infected area expands quickly and fever, blisters, skin discoloration, numbness, fatigue and flu-like symptoms may occur.
How do you detect flesh-eating bacteria early?
Carefully monitoring any skin wound or infection site for rapid expansion, worsening pain, fever, blisters and skin discoloration can help detect a developing necrotizing fasciitis infection early.
What does a wound infected with flesh-eating bacteria look like?
The infection starts as a red, swollen lesion or wound. As it progresses, the area rapidly expands, fluid-filled blisters emerge, and the tissue becomes necrotic, turning black or purple in color.
Can you survive flesh-eating bacteria?
Yes, with prompt surgical debridement and intravenous antibiotics, flesh-eating bacterial infections can be successfully treated, especially if caught early before progression to sepsis.
What are the stages of necrotizing fasciitis infections?
The stages are: 1) localized infection, 2) rapid progression as infection spreads under skin, 3) widespread tissue necrosis, 4) systemic sepsis as bacteria enter bloodstream.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Add Comment